Cargando…

Gene Expression of CXCL1 (GRO-α) and EGF by Platelets in Myeloproliferative Neoplasms

Detalles Bibliográficos
Autores principales:	Collinson, Ryan J., Mazza-Parton, Allegra, Fuller, Kathryn A., Linden, Matthew D., Erber, Wendy N., Guo, Belinda B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592996/ https://www.ncbi.nlm.nih.gov/pubmed/33134870 http://dx.doi.org/10.1097/HS9.0000000000000490

Ejemplares similares

Paving the way to improve therapy for Myeloproliferative Neoplasms
por: Bywater, Megan, et al.
Publicado: (2022)

Dysregulation of the intrinsic apoptotic pathway mediates megakaryocytic hyperplasia in myeloproliferative neoplasms
por: Malherbe, Jacques A J, et al.
Publicado: (2016)

Clonal Architecture in Myeloproliferative Neoplasms: Old Dog, New Tricks?
por: Godfrey, Anna L.
Publicado: (2023)

Inflammatory picture of Philadelphia-negative myeloproliferative neoplasms()
por: Pagnano, Katia Borgia Barbosa
Publicado: (2018)

Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms
por: Marin Oyarzún, Cecilia P., et al.
Publicado: (2019)

Message in a platelet: decoding platelet transcriptomes in myeloproliferative neoplasms
por: Shapiro, Susan, et al.
Publicado: (2021)

Longitudinal Cytokine Profiling Identifies GRO-α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia
por: Øbro, Nina F., et al.
Publicado: (2020)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter?
por: Koçak Göktürk, Ilgın, et al.
Publicado: (2023)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count
por: Divoux, Marion, et al.
Publicado: (2020)

Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms
por: Bekendam, Roelof H., et al.
Publicado: (2023)

Deactylase inhibition in myeloproliferative neoplasms
por: Mithraprabhu, Sridurga, et al.
Publicado: (2010)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

The Hematopoietic Niche in Myeloproliferative Neoplasms
por: Schmitt-Graeff, Annette H., et al.
Publicado: (2015)

Calreticulin Mutations in Myeloproliferative Neoplasms
por: Lavi, Noa
Publicado: (2014)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Apoptosis deregulation in myeloproliferative neoplasms
por: Tognon, Raquel, et al.
Publicado: (2013)

Mutant Calreticulin in the Myeloproliferative Neoplasms
por: Prins, Daniel, et al.
Publicado: (2020)

Experimental Modeling of Myeloproliferative Neoplasms
por: Lanikova, Lucie, et al.
Publicado: (2019)

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
por: Person, Fermin, et al.
Publicado: (2021)

Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms
por: Shen, Zhu, et al.
Publicado: (2021)

Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The “Circulating Wound” Model
por: Lucchesi, Alessandro, et al.
Publicado: (2021)

Platelet proteo-transcriptomic profiling validates mediators of thrombosis and proteostasis in patients with myeloproliferative neoplasms
por: Kelliher, Sarah, et al.
Publicado: (2023)

Myocardial infarction as a thrombotic complication of myeloproliferative disorders
por: Petrou, Emmanouil, et al.
Publicado: (2016)

PD-1 inhibition in advanced myeloproliferative neoplasms
por: Hobbs, Gabriela, et al.
Publicado: (2021)

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
por: Ianotto, Jean-Christophe, et al.
Publicado: (2018)

Creating the Functional Single-Ring GroEL-GroES Chaperonin Systems via Modulating GroEL-GroES Interaction
por: Illingworth, Melissa, et al.
Publicado: (2017)

Philadelphia-negative chronic myeloproliferative neoplasms
por: Bittencourt, Rosane Isabel, et al.
Publicado: (2012)

CALR mutation characterization in myeloproliferative neoplasms
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2016)

Genetic–pathologic characterization of myeloproliferative neoplasms
por: Kim, Yonggoo, et al.
Publicado: (2016)

The Role of New Technologies in Myeloproliferative Neoplasms
por: Palumbo, Giuseppe A., et al.
Publicado: (2019)

Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
por: Kjær, Lasse
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hr97mqedrvm5v9ed0snsmn4gv0